US 12,611,421
Application 18/533,373 · Granted Apr 28, 2026
Hydroxypropyl beta-cyclodextrin compositions and methods
Estimated expiration
June 9, 2036
9y 203d remaining
Earliest effective filing
Jun 9, 2016
+ 20 years
Jun 9, 2036
PTA +257d
Feb 21, 2037
TD cap (US 9,675,634)
Jun 9, 2036
Final
Jun 9, 2036
- Earliest effective filing
- Jun 9, 2016
- + 20 years
- Jun 9, 2036
- PTA +257d
- Feb 21, 2037
- TD cap (US 9,675,634)
- Jun 9, 2036
- Final
- Jun 9, 2036
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- December 8, 2023
- Earliest effective filing
- June 9, 2016
- Issue date
- April 28, 2026
- PTA
- +257 days
- Base expiry (before PTA)
- June 9, 2036
June 9, 2016 + 20 years = June 9, 2036 + 257 PTA days = February 21, 2037
- Continuation of application 17/970,080, filed Oct 20, 2022, issued as US 11,938,144
- Continuation of application 17/745,464, filed May 16, 2022, issued as US 11,590,159
- Continuation of application 17/036,148, filed Sep 29, 2020, issued as US 11,406,657
- Continuation of application 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
- Continuation of application 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
- Continuation of application 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
- Continuation of application 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
- Continuation of application 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
- Continuation of application 15/178,153, filed Jun 9, 2016
- Continuation of application 15/178,153, filed Jun 9, 2016
- Continuation of application 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
- Continuation of application 15/178,153, filed Jun 9, 2016
- Continuation of application 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
- Continuation of application 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
- Continuation of application 15/178,153, filed Jun 9, 2016
- Continuation of application 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
- Continuation of application 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
- Continuation of application 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
- Continuation of application 15/178,153, filed Jun 9, 2016
- Continuation of application 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
- Continuation of application 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
- Continuation of application 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
- Continuation of application 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
- Continuation of application 15/178,153, filed Jun 9, 2016
- Continuation of application 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
- Continuation of application 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
- Continuation of application 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
- Continuation of application 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
- Continuation of application 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
- Continuation of application 15/178,153, filed Jun 9, 2016
- Continuation of application 17/036,148, filed Sep 29, 2020, issued as US 11,406,657
- Continuation of application 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
- Continuation of application 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
- Continuation of application 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
- Continuation of application 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
- Continuation of application 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
- Continuation of application 15/178,153, filed Jun 9, 2016
- Continuation of application 17/745,464, filed May 16, 2022, issued as US 11,590,159
- Continuation of application 17/036,148, filed Sep 29, 2020, issued as US 11,406,657
- Continuation of application 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
- Continuation of application 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
- Continuation of application 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
- Continuation of application 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
- Continuation of application 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
- Continuation of application 15/178,153, filed Jun 9, 2016
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
- PRO62/345,721 — Provisional — not used for base term
- PRO62/331,385 — Provisional — not used for base term
- PRO62/314,765 — Provisional — not used for base term
- PRO62/308,736 — Provisional — not used for base term
- PRO62/276,728 — Provisional — not used for base term
- PRO62/263,599 — Provisional — not used for base term
- PRO62/249,876 — Provisional — not used for base term
- PRO62/245,974 — Provisional — not used for base term
- PRO62/189,114 — Provisional — not used for base term
- PRO62/175,075 — Provisional — not used for base term
- PRO62/173,889 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to June 9, 2036 (earliest expiring referenced patent: US 9,675,634)
US 9,675,634· Application 15/288,876Capping patent
Hydroxypropyl beta-cyclodextrin compositions and methods
- Filing date
- Oct 7, 2016
- Earliest effective filing
- Jun 9, 2016
- Issue date
- Jun 13, 2017
- PTA
- 0 days
- Calculated expiration
- Jun 9, 2036
Continuation of 15/178,153, filed Jun 9, 2016
Jun 9, 2016 + 20y = Jun 9, 2036
US 11,517,585· Application 17/745,516
Hydroxypropyl beta-cyclodextrin compositions and methods
- Filing date
- May 16, 2022
- Earliest effective filing
- Jun 9, 2016
- Issue date
- Dec 6, 2022
- PTA
- 0 days
- Calculated expiration
- Jun 9, 2036
Continuation of 17/036,148, filed Sep 29, 2020, issued as US 11,406,657
Continuation of 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Jun 9, 2016 + 20y = Jun 9, 2036
US 11,529,366· Application 17/745,505
Hydroxypropyl beta-cyclodextrin compositions and methods
- Filing date
- May 16, 2022
- Earliest effective filing
- Jun 9, 2016
- Issue date
- Dec 20, 2022
- PTA
- 0 days
- Calculated expiration
- Jun 9, 2036
Continuation of 17/036,148, filed Sep 29, 2020, issued as US 11,406,657
Continuation of 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Jun 9, 2016 + 20y = Jun 9, 2036
US 11,534,455· Application 17/745,487
Hydroxypropyl beta-cyclodextrin compositions and methods
- Filing date
- May 16, 2022
- Earliest effective filing
- Jun 9, 2016
- Issue date
- Dec 27, 2022
- PTA
- 0 days
- Calculated expiration
- Jun 9, 2036
Continuation of 17/036,148, filed Sep 29, 2020, issued as US 11,406,657
Continuation of 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Jun 9, 2016 + 20y = Jun 9, 2036
US 11,534,456· Application 17/745,491
Hydroxypropyl beta-cyclodextrin compositions and methods
- Filing date
- May 16, 2022
- Earliest effective filing
- Jun 9, 2016
- Issue date
- Dec 27, 2022
- PTA
- 0 days
- Calculated expiration
- Jun 9, 2036
Continuation of 17/036,148, filed Sep 29, 2020, issued as US 11,406,657
Continuation of 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Continuation of 16/430,664, filed Jun 4, 2019, issued as US 10,933,083
Continuation of 16/372,899, filed Apr 2, 2019, issued as US 10,709,730
Continuation of 16/134,028, filed Sep 18, 2018, issued as US 10,300,086
Continuation of 15/499,831, filed Apr 27, 2017, issued as US 10,258,641
Continuation of 15/288,876, filed Oct 7, 2016, issued as US 9,675,634
Continuation of 15/178,153, filed Jun 9, 2016
Jun 9, 2016 + 20y = Jun 9, 2036
Notes (1)
- [TD_REFS_TRUNCATED] Found 27 TD references; resolving first 5 only
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
You have the date. Your AI can have the file.
Application 18/533,373 · US 12,611,421
PatentReply compiles the prosecution history behind US 12,611,421: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new published application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12611421Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.